A unique probiotic formulation, L-39, has great promise as a pharmaceutical treatment for a common illness. When it hits a stumbling block in its latest clinical trial, Hilde Dach, the scientist leading the research at German drug maker Caliska, faces the prospect that the company may want to reimagine her product as a nutraceutical, because the regulatory hurdles would be easier to clear. Is the company merely hedging its bets to avoid big losses, or is it abandoning the possibility of achieving loftier aims and potentially bigger profits? Expert commentary comes from Jonathan Lewis, CEO of Ziopharm Oncology, and Colin Hill, president of the International Scientific Association for Probiotics and Prebiotics. This HBR Case Study includes both the case and the commentary. For teaching purposes, this Reprint is also available in two other versions: case study-only, reprint R1311X, and commentary-only, R1311Z.

【書誌情報】

ページ数：7ページ

サイズ：A4

商品番号：HBSP-R1311M

発行日：2013/11/1

登録日：2017/6/5